Literature DB >> 6514305

The use of Amsler grids in early chloroquine retinopathy.

M Easterbrook.   

Abstract

A survey of Canadian ophthalmologists and rheumatologists suggests that there is a significant incidence of definite chloroquine retinopathy in their patients. As hydroxychloroquine and chloroquine appear to be better tolerated and less toxic than some other drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus, there is a need for a simple, patient-administered test for early diagnosis of chloroquine retinopathy. The Amsler grid and smaller Yannuzzi modified Amsler grid are simple, inexpensive, and correlate well with scotomas found with static and kinetic perimetry.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6514305     DOI: 10.1016/s0161-6420(84)34139-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.

Authors:  Timothy Y Y Lai; Jasmine W S Ngai; Wai-Man Chan; Dennis S C Lam
Journal:  Doc Ophthalmol       Date:  2006-06-28       Impact factor: 2.379

Review 2.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

3.  Detecting chloroquine retinopathy: electro-oculogram versus colour vision.

Authors:  A S Neubauer; K Samari-Kermani; U Schaller; U Welge-Lübetaen; G Rudolph; T Berninger
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

Review 4.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

5.  A novel Bayesian adaptive method for mapping the visual field.

Authors:  Pengjing Xu; Luis Andres Lesmes; Deyue Yu; Zhong-Lin Lu
Journal:  J Vis       Date:  2019-12-02       Impact factor: 2.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.